New drug combo aims to wipe out lingering cancer after transplant

This study is testing whether a combination of three drugs (isatuximab, lenalidomide, and dexamethasone) can eliminate tiny amounts of remaining cancer cells in multiple myeloma patients who have already received a stem cell transplant. The trial will enroll 30 adults who still show minimal residual disease after their transplant. Researchers will give participants the drug combination for 12 months and measure whether it clears these remaining cancer cells from the bone marrow.